Brief: Theriva Biologics - European Commission Granted Orphan Medicinal Product Designation To VCN-01 For Treatment Of Retinoblastoma
16/10/2024 13:03
Oct 16 (Reuters) - Theriva Biologics Inc TOVX.A :
* THERIVA BIOLOGICS: EUROPEAN COMMISSION GRANTED ORPHAN
MEDICINAL
PRODUCT DESIGNATION TO VCN-01 FOR TREATMENT OF RETINOBLASTOMA
Source text for Eikon: ID:nGNE7G9cYr
Further company coverage: TOVX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theriva Biologics
See all newsTheriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Brief: Theriva™ Biologics Announces Upcoming Presentation Of Additional Data From The Virage Phase 2B Clinical Trial Of Vcn-01 In Metastatic Pancreatic Cancer At Aacr 2026 Annual Meeting
Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
Brief: Theriva Biologics Implements 32% Workforce Reduction - SEC Filing
Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025